Synthesis, Crystallization Studies, and in vitro Characterization of Cinnamic Acid Derivatives as
<i>Sm</i>
HDAC8 Inhibitors for the Treatment of Schistosomiasis
作者:Theresa Bayer、Alokta Chakrabarti、Julien Lancelot、Tajith B. Shaik、Kristin Hausmann、Jelena Melesina、Karin Schmidtkunz、Martin Marek、Frank Erdmann、Matthias Schmidt、Dina Robaa、Christophe Romier、Raymond J. Pierce、Manfred Jung、Wolfgang Sippl
DOI:10.1002/cmdc.201800238
日期:2018.8.10
million people worldwide and for which the control strategy relies on mass treatment with only one drug: praziquantel. Based on the 3‐chlorobenzothiophene‐2‐hydroxamicacid J1075, a series of hydroxamicacids with different scaffolds were prepared as potential inhibitors of Schistosoma mansoni histonedeacetylase 8 (SmHDAC8). The crystal structures of SmHDAC8 with four inhibitors provided insight into the
[EN] SMALL MOLECULE INHIBITORS OF HISTONE DEACTEYLASES<br/>[FR] INHIBITEURS À PETITE MOLÉCULE D'HISTONE DÉSACÉTYLASES
申请人:NUPOTENTIAL INC
公开号:WO2013059582A2
公开(公告)日:2013-04-25
The disclosure relates to small molecules and methods, compositions, and kits comprising these small molecules. In still another embodiment, the disclosure relates to small molecules that inhibit HDAC activity. In yet another embodiment, the disclosure relates to small molecules for inhibiting the growth of cancer cells. In still another embodiment, the disclosure relates to small molecules for reprogramming a cell.
Myeloperoxidase (MPO) is known to cause oxidative stress and inflammation leading to cardiovasculardisease (CVD) complications. MPO‐mediated oxidation of lipoproteins leads to dysfunctional entities altering the landscape of lipoprotein functionality. The specificity of guaiacolderivatives toward preventing MPO‐mediated oxidation to limit MPO's harmful effects is unknown. Diligent in silico studies